Director Kimberly Manhard filed a Form 4 on September 15, 2026, disclosing the sale of 1,500 shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX) common stock across three transactions between September 11 and September 15, 2026, through a revocable trust.

Key Highlights

  • Three sales executed: 500 shares sold on September 11, 500 on September 14, and 500 on September 15, 2026.
  • Prices per transaction: $111.775 on September 11, $110.26 on September 14, and $105.05 on September 15, according to the filing.
  • Selling entity: All shares were disposed of through the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012, held indirectly.
  • Remaining ownership: Following the three sales, 7,500 shares remain beneficially owned indirectly through the trust, the filing states.
  • Reporting person's role: Kimberly Manhard is identified as a Director of Inhibrx Biosciences, Inc.

Manhard Trust Reduces Inhibrx Biosciences Holdings Across Three Consecutive Trading Days

According to the Form 4 filed with the SEC, Director Kimberly Manhard disposed of a total of 1,500 shares of Inhibrx Biosciences common stock between September 11 and September 15, 2026. Each transaction involved 500 shares sold under transaction code "S," indicating open-market sales. The filing records sale prices of $111.775, $110.26, and $105.05 for the three respective dates.

All transactions were conducted through the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012, which directly holds the securities. The filing explains that Manhard serves as trustee of that trust and, in that capacity, "may be deemed to indirectly beneficially own the securities owned by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012." Accordingly, the filing classifies the ownership form as indirect.

Prior to the reported transactions, the trust held 9,000 shares, based on the sequence shown in the filing: 9,000 reduced to 8,500 after the September 11 sale, 8,000 after September 14, and 7,500 following the September 15 sale. The Form 4 was signed by Kelly D. Deck as attorney-in-fact for Kimberly Manhard and dated September 15, 2026. No derivative securities were reported in Table II.

What Was Disclosed

Director Kimberly Manhard disclosed three open-market sales of Inhibrx Biosciences common stock totaling 1,500 shares between September 11 and September 15, 2026, all executed indirectly through a revocable trust, leaving 7,500 shares beneficially owned.